Orbis Health Solutions' Personalized Cancer Vaccine (TLPO)

Many traditional cancer treatments, such as chemotherapy, work by killing off cancer cells but also kill off non-cancerous cells throughout the body. This can cause a range of side effects including hair loss, nausea, vomiting, or may damage the person's immune system.

Dr. Thomas Wagner's mission: Develop a cancer treatment without debilitating side effects.

His solution: A personalized vaccine, the TLPO (tumor lysate particle only), made from each patient's tumor cells.

The tumor lysate particle only (TLPO) vaccine uses a person's tumor cells to identify particular parts that are then presented back in the body using the vaccine in a way that can stimulate their immune system to gain the ability to detect these cancer cells like an infection, allowing the immune system to fight the cancer itself.

Results so far:

• Promising Phase 2 data: 95% of melanoma patients alive after 3 years, 64% disease-free.
• FDA greenlit Phase 3 trial: enrolling 500 people, could launch this year.

Hope for the future:

• TLPO vaccine could be a game-changer in cancer treatment, especially with early detection.
• Personalized approach might offer effective treatment with minimal side effects.

Key takeaway: Orbis Health Solutions' personalized cancer vaccine shows promising results, but larger trials and further research are needed before it can be widely available.

Source: ABC News

TECHNOLOGY

Orbis Health Solutions is an assignee for multiple patent applications. US10869885B2 is one of its key patents. 

US10869885B2 Patent Claims (Inventor: Thomas E. Wagner, Assignee: Orbis Health Solutions LLC.):

This patent application is a Continuation of U.S. application Ser. No. 15/864,496, filed Jan. 8, 2018, which is a Continuation of U.S. application Ser. No. 14/019,025, filed Sep. 5, 2013, which claims priority from U.S. provisional application No. 61/697,498, filed Sep. 6, 2012. 

Tumor cells, often equipped with mutations that help them evade immune detection, pose a significant challenge. Researchers have explored using dendritic cells, skilled antigen presenters, to activate the immune system against these stealthy enemies. One approach involved "pulsing" dendritic cells with peptides or tumor lysate, aiming to trigger an immune response in melanoma patients. While Thomas E. Wagner developed a patented method. Here is the independent claim:

1. A method for producing a tumor lysate loaded particle comprising de:

(i) contacting a suspension of yeast cell wall particles (YCWPs) with a tumor lysate, wherein contacting the suspension comprises:

(a) incubating the suspension of YCWPs with the tumor lysate,

(b) freeze-drying the suspension of YCWPs, and

(c) washing the YCWPs, wherein steps (a)-(b) are repeated at least once with a step of adding water into the yeast cell particle before step (a) is repeated; and

(ii) freeze-drying the suspension of YCWPs and the tumor lysate to produce a tumor lysate loaded particle.

Example 12/Table 1 of the patent shows the in vitro data.  For details and accuracy, please check with US10869885B2.

Orbis Health Solutions is a privately held biotechnology company, it was founded in 2009. 

INTERESTING ARTICLES

Elizabeth Lee Carpenter et al, Prospective, randomized, double-blind phase 2B trial of the TLPO and TLPLDC vaccines to prevent recurrence of resected stage III/IV melanoma: a prespecified 36-month analysis, J Immunother Cancer. 2023 Aug;11(8): e006665.  

Patrick M McCarthy et al, Tumor infiltrating lymphocytes as an endpoint in cancer vaccine trials ,  Front Immunol . 2023 Mar 7:14:1090533.

Alexandra M Adams et al, Divergent clinical outcomes in a phase 2B trial of the TLPLDC vaccine in preventing melanoma recurrence and the impact of dendritic cell collection methodology: a randomized clinical trial, Cancer Immunol Immunother  . 2023 Mar;72(3):697-705.